186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
| Autor: | Fehm, T.N., Cottone, F., Dunton, K., André, F., Krop, I., Park, Y.H., De Laurentiis, M., Miyoshi, Y., Armstrong, A., Borrego, M. Ruiz, Yerushalmi, R., Duhoux, F.P., Takano, T., Lu, W., Livings, C., Egorov, A., Kim, S-B. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|